 This study, for patients who have Stage IIIC colorectal cancer and who underwent 5-fluorouracilleucovorin with oxaliplatin FOLFOX chemotherapy after surgery, will test to see if regorafenib given after the completion of FOLFOX improves treatment, compared to standard of care SOC, which is no further treatment. 